These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Phase III trial of IL-2. AIDS Patient Care STDS; 1999 Dec; 13(12):753-4. PubMed ID: 10743542 [No Abstract] [Full Text] [Related]
11. Report from the 16th Conference on Retroviruses and Opportunistic Infections. No clinical benefit from adding IL-2 to ART. Henry K J Watch AIDS Clin Care; 2009 Apr; 21(4):29-30. PubMed ID: 19544613 [No Abstract] [Full Text] [Related]
12. [Use of interleukin-2 (proleukin, aldesleukin) in oncological practice]. Gershanovich ML Vopr Onkol; 2003; 49(6):776-82. PubMed ID: 14976930 [No Abstract] [Full Text] [Related]
13. Improved treatment results with interleukin-2. HIV Hotline; 1998 May; 8(2):13-4. PubMed ID: 11365363 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-2 in combination with zidovudine and didanosine is able to maintain high levels of CD4 cells and undetectable HIV viraemia. Simonelli C; Zanussi S; Comar M; Vaccher E; Giacca M; De Paoli P; Tirelli U AIDS; 1998 Jan; 12(1):112-3. PubMed ID: 9456263 [No Abstract] [Full Text] [Related]
15. Definitive results: IL-2 does not benefit HIV-infected patients. Interleukin-2 improves CD4-cell recovery in patients on antiretroviral therapy, but that benefit does not translate into lower risks for disease or death. Hicks CB J Watch AIDS Clin Care; 2010 Jan; 22(1):4. PubMed ID: 20617576 [No Abstract] [Full Text] [Related]